- About TapImmune
- News & Media
- Contact Us
Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials SEATTLE, July 27, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has...
Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in...